Medical Director - Oncology
- Location
- Toronto, Canada
- Employment
- Full Time
- Work model
- Hybrid
- Level
- Staff
- Salary
- $124.5k – $182.6k/yr
- Posted
About this role
At Lilly, the work is demanding because patients are waiting. We unite caring with discovery to help make life better for people around the world, knowing that every decision, every detail, and every day matters. Headquartered in Indianapolis, Indiana, our over 50,000 employees around the globe take on complex challenges to discover and deliver life-changing medicines, strengthen how health is understood and managed, and support the communities we serve. This is hard, urgent, selfless work—but it’s work worth doing. If you’re driven by purpose and ready to bring your best to work that truly matters for patients, we invite you to join us.
Position
Summary: Eli Lilly Canada is currently searching for a Medical Director for the Oncology Business Unit to lead the lung cancer and emerging solid tumour portfolio. As the Medical Director, Oncology, you will serve as a core scientific expert on the Canadian Medical Affairs team, playing an integral role across launch readiness strategic planning, launch activities, stakeholder engagement, and evidence generation. You will bridge medical strategy and local execution, working closely with cross-functional teams to ensure patients, healthcare providers (HCPs), and payers receive accurate, timely, and high-quality scientific information. Location: This is a hybrid role – onsite presence at our Toronto office will be 10 days or more per month (or at least 50% of the time), determined in collaboration with your manager and based on business needs. At Lilly Canada, there are multiple levels available based on the candidates experience, background, and qualifications. For transparency, the ranges for this position are: • Sr Advisor: $124,500 - $182,600 • Director: $137,250 - $201,300 This role is eligible for additional forms of compensation, such as participation in the Lilly Bonus Program. This posting is for an existing vacancy. Medical & Scientific Leadership Own and lead the development of the Canadian oncology medical strategy for lung cancer and emerging solid tumours, translating global medical plans into locally relevant priorities that address the needs of patients, HCPs, and payers. Develop, execute, and continuously optimize the annual medical tactical plan, setting clear objectives, milestones, and success metrics in alignment with the brand and Medical Affairs teams. Manage the brand medical affairs budget, including projected budget needs, and diligent tracking of expenditures to ensure activities are delivered on time and within approved financial parameters. Act as the Canadian medical expert for the oncology product portfolio, providing evidence-based input to support brand strategy, product launches, and lifecycle management for both marketed brands and pipeline assets. Contribute medical and clinical insight to the development and review of promotional materials, medical information letters, slide decks, abstracts, and publications. Provide medical education and training to cross-functional internal partners, including sales representatives and medical science liaisons (MSLs). Represent the Canadian medical perspective in Global, International Business Unit, and Medical Affairs planning forums, and communicate local research needs to global Development, Medical Affairs, Real World Evidence, and Early Phase/Translational Medicine teams. Keep current with the pre-clinical and clinical data relevant to each molecule, and represent the clinical needs of Canada in the development of clinical strategies, development plans, and study protocol design. Stakeholder Engagement Understand and anticipate the scientific information needs of Canadian stakeholders (patients, HCPs, and payers), and address their questions in a timely fashion. Build and maintain collaborative relationships with Thought Leaders (TLs), academic centers, patient advocacy groups, and relevant professional societies across Canada. Lead advisory board meetings,